Loading data for TARA — first visit, this takes a few seconds.
Protara Therapeutics, Inc.
3.75 -0.16 (-4.09%)
- Market Cap
- $218.7M
- Volume
- 900K
- Dividend yield
- n/a
- Next earnings date
- Nov 10, 2026
Protara Therapeutics, Inc. (TARA) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | n/a |
| EPS | -$0.36 | -$0.05 | -2.86% |
Metrics
- Bid
- 2.92
- Market Cap
- 219M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -70M
- 1.49
- -1.38
- n/a
- -2.19
- P/B (ttm)
- 1.36
- P/S (ttm)
- n/a
- Earnings Date
- Nov 10, 2026
- Ask
- 5.12
- Volume
- 899,544
- Avg. Volume (20D)
- 507,719
- Open
- 3.91
- Previous Close
- 3.91
- Day's Range
- 3.74 - 3.94
- 52-Week Range
- 3.02 - 7.82
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Protara Therapeutics, Inc.
View profile →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Industry Biotechnology
Sector Healthcare
IPO Date Oct 22, 2014
Employees 46
Stock Exchange NasdaqGM
Ticker Symbol TARA
Website https://www.protaratx.com